GenMark Diagnostics (GNMK) Shares are Up 0.85%

GenMark Diagnostics (GNMK) : Traders are bullish on GenMark Diagnostics (GNMK) as it has outperformed the S&P 500 by a wide margin of 35.74% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.69%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.85% in the last 1 week, and is up 35.01% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 18.53% and the 50-Day Moving Average is 22.8%.The 200 Day SMA reached 59.57%


GenMark Diagnostics (NASDAQ:GNMK): After opening at $10.83, the stock dipped to an intraday low of $10.83 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $11.98 and the buying power remained strong till the end. The stock closed at $11.8 for the day, a gain of 8.46% for the day session. The total traded volume was 600,189. The stocks close on the previous trading day was $11.8.

GenMark Diagnostics (GNMK) : The highest short term price target forecast on GenMark Diagnostics (GNMK) is $17 and the lowest target price is $11. A total of 4 equity analysts are currently covering the company. The average price of all the analysts is $13.25 with a standard deviation of $2.63.

GenMark Diagnostics, Inc. (GenMark) is a molecular diagnostics company. The Company is focused on developing and commercializing its eSensor detection technology. The Companys electrochemical technology enables detection of multiple distinct biomarkers in a single sample. The Companys XT-8 system received 510(k) clearance from the United States Food and Drug Administration (FDA) and is designed to support a range of molecular research and diagnostic tests with a workstation and disposable test cartridges. Its XT-8 system supports up to 24 independent test cartridges, each of which can be run independently, resulting in a workflow for its focused customers, which are primarily hospitals and reference laboratories. It has an installed base of approximately 540 XT-8 analyzers, or placements, with its customers.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.